Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

NCT03056755
View directory record Official record
Conditions
Breast Cancer
Interventions
Alpelisib, Fulvestrant, Letrozole, Goserelin, Leuprolide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

KULEA-NET: A Mobile Application for African American/Black Mothers to Promote Exclusive and Continuous Breastfeeding

NCT05985876
View directory record Official record
Conditions
Breastfeeding, Exclusive Breastfeeding
Interventions
KULEA-NET application, Control Group: Usual Care
Behavioral
Lead sponsor
Benten Technologies, Inc.
Industry
Eligibility
18 Years to 44 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Hyattsville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03412890
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
104
States / cities
Andalusia, Alabama • Birmingham, Alabama • Mobile, Alabama + 84 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 2 Interventional

COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy

NCT02465320
View directory record Official record
Conditions
Endometrial Biopsy
Interventions
COL-1077, Placebo
Drug
Lead sponsor
Juniper Pharmaceuticals, Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
23
States / cities
Norwalk, California • Colorado Springs, Colorado • Lakewood, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

NCT00200174
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene followed by combination therapy, Exemestane followed by combination therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 3 Interventional

Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)

NCT00329355
View directory record Official record
Conditions
Migraine, Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
35
States / cities
Chandler, Arizona • Irvine, California • Redondo Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease

NCT00709891
View directory record Official record
Conditions
Human Papilloma Virus (HPV)
Interventions
cobas® 4800 HPV Test
Device
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older · Female only
Enrollment
47,208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
61
States / cities
Enterprise, Alabama • Hoover, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

NCT01257841
View directory record Official record
Conditions
Healthy
Interventions
Leptin administration, Fasting
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2010 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01994473
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo, SEP-363856 Open Label
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 30, 2026, 6:04 AM EDT
Not listed Phase 3 Interventional Results available

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

NCT00108745
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Clinical Observation, Laboratory Biomarker Analysis, Paclitaxel, Paclitaxel Poliglumex, Quality-of-Life Assessment
Other · Drug · Procedure
Lead sponsor
GOG Foundation
Network
Eligibility
Female only
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
315
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Bioavailability of Various Formulations of GDC-0134 in Healthy Female Participants of Non-Childbearing Potential

NCT03807739
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GDC-0134 F09 Formulation, GDC-0134 F15 Formulation, GDC-0134 F16 Formulation
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 30, 2026, 6:04 AM EDT
Active, not recruiting No phase listed Observational

Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer

NCT04569773
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Impact of Event Scale-Revised, Reproductive Concerns Scale, Decision Regret Scale
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

NCT07427394
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Camizestrant, Atirmociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
St Louis, Missouri • East Providence, Rhode Island • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

NCT01365156
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Cervical Cancer
Interventions
Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project RESIST: Increasing Resistance to Tobacco Marketing Among Young Adult Sexual Minority Women Using Inoculation Message Approaches

NCT04812795
View directory record Official record
Conditions
Cigarette Smoking Behavior
Interventions
Culturally tailored anti-smoking messages, Non-culturally tailored interventions
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 30 Years
Enrollment
2,214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Stanford, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.

NCT00781586
View directory record Official record
Conditions
Energy Expenditure
Interventions
One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350), Caffeine, Placebo
Dietary Supplement · Drug
Lead sponsor
Bayer
Industry
Eligibility
25 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD Study to Evaluate Safety, Tolerability, and Pharmacokinetic Profile of AMN1126 in Healthy Post-Menopausal Females

NCT06467201
View directory record Official record
Conditions
Healthy Postmenopausal Women
Interventions
KSHN001126 150mg, KSHN001126 300mg, KSHN001126 600mg
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Not applicable Interventional

G.R.I.T. - Goal-directed Resilience Intervention Training

NCT03890029
View directory record Official record
Conditions
Chronic Post-Traumatic Stress Disorder
Interventions
Intervention Training, Control Condition
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Oct 30, 2026, 6:04 AM EDT
Completed No phase listed Observational Results available

Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence

NCT02348112
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Altis Single Incision Sling, Transobturator or Retropubic Sling
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
26
States / cities
Stanford, California • Denver, Colorado • Hialeah, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 30, 2026, 6:04 AM EDT
Recruiting Phase 4 Interventional

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

NCT07476339
View directory record Official record
Conditions
HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions
Bictegravir, emtricitabine, and tenofovir alafenamide
Drug
Lead sponsor
CAN Community Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 3 Interventional Results available

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
Interventions
Exemestane, Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Radiation Therapy, Tamoxifen, Triptorelin
Drug · Other · Procedure + 1 more
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 65 Years · Female only
Enrollment
3,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2024
U.S. locations
480
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 323 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 6:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Averting NAS Among Opioid-Using Young Women Receiving MAT Using Buprenorphine

NCT04611659
View directory record Official record
Conditions
Opioid-use Disorder, Contraception, Neonatal Abstinence Syndrome
Interventions
Motivational Interviewing and Educational Training (MIET)
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of OsrHSA in Adult Healthy Male and Female Volunteers

NCT04384523
View directory record Official record
Conditions
Ascites Hepatic
Interventions
OsrHSA 20 mg/kg IV, OsrHSA 40 mg/kg IV, OsrHSA 80 mg/kg IV, OsrHSA 140 mg/kg IV, OsrHSA 200 mg/kg IV, Placebo
Drug · Other
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 30, 2026, 6:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

NCT01511497
View directory record Official record
Conditions
Pain, Migraine Disorders
Interventions
PF-04427429, Normal saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 30, 2026, 6:04 AM EDT